Abstract
Three adolescents with central nervous system (CNS) negative acute myeloid leukaemia (AML) refused cranial irradiation for CNS prophylaxis. Instead, these patients received four doses of 50 mg of intrathecal (IT) liposomal cytarabine on day 1, 15, 43 and 71 of maintenance therapy. Corticosteroids were given to prevent chemical arachnoiditis. All patients developed bilateral papilloedema after the third or fourth dose of liposomal cytarabine, local side effects were observed in two patients. Under prolonged dexamethasone therapy, side effects resolved completely. As reversible neuroophthalmological side effects caused by intrathecal liposomal cytarabine can also be observed under low-dose maintenance therapy in patients with CNS negative AML, it should be used with caution in children and adolescents.
Similar content being viewed by others
References
Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W et al (2007) Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 29:222–226 doi:10.1097/MPH.0b013e318041f112
Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ et al (2004) Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 22:3916–3921 doi:10.1200/JCO.2004.01.046
Chamberlain MC, Glantz MJ (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphatic leukaemia. Blood 110:1698 author reply 1698–1699 doi:10.1182/blood-2007-02-073536
Chamberlain MC, Kormanik P, Howell SB, Kim S (1995) Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52:912–917
Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al (2005) Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 19:2030–2042 doi:10.1038/sj.leu.2403920
Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T (2004) Early deaths and treatment related mortality in children undergoing therapy for acute myeloid leukaemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22:4384–4393 doi:10.1200/JCO.2004.01.191
Glantz MJ, La Folette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116
Goshen Y, Stark B, Kornreich L, Michowiz S, Feinmesser M, Yaniv I (2007) High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 49:294–297 doi:10.1002/pbc.21153
Hata M, Ogino I, Aida N, Saito K, Omura M, Kigasawa H et al (2001) Prophylactic cranial irradiation of acute lymphoblastic leukemia in childhood: outcomes of late effects on pituitary function and growth in long-term survivors. Int J Cancer 96(Suppl):117–124 doi:10.1002/ijc.10348
Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F et al (2007) Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214–3218 doi:10.1182/blood-2006-08-043646
McClune B, Buadi FK, Aslam N, Przepiorka D (2007) Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukaemia and high-grade lymphoma. Leuk Lymphoma 48:1849–1851 doi:10.1080/10428190701573232
Pui C-H (2007) Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma 48:1672–1673 doi:10.1080/10428190701573687
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sommer, C., Lackner, H., Benesch, M. et al. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Ann Hematol 87, 887–890 (2008). https://doi.org/10.1007/s00277-008-0521-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0521-9